You are here
Determining the right patients for neoadjuvant/adjuvant therapy
Dr Payne emphasizes the complexity of treatment decisions for high-risk prostate cancer: there is no standard definition of “high risk”, and this group may include locally advanced and localized tumours with Gleason score ≥ 8 or PSA ≥ 20 ng/mL. Several treatments are recommended. Whether the best agent for long-term adjuvant androgen suppression is LHRH or GnRH is under investigation.